JOHNSON & JOHNSON is 2.0x more valuable than AstraZeneca PLC by market capitalization ($573.98 B vs $286.27 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | JNJ | AZN |
|---|---|---|
| Market cap | $573.98 B | $286.27 B |
| US-listed rank | #20 | #45 |
| Revenue (latest FY) | $94.19B | - |
| Net income (latest FY) | $26.80B | - |
| Net margin | 28.5% | - |
| P/E (trailing FY) | 21.4 | - |
| SEC filings | 984 | 1,004 |
JOHNSON & JOHNSON is 2.0x more valuable than AstraZeneca PLC by market capitalization ($573.98 B vs $286.27 B).
Full pages: JOHNSON & JOHNSON and AstraZeneca PLC, or browse the full rankings.